In 2015, there will be an estimated 20,000 cases of ovarian cancer (OC) resulting in 14,000 deaths. The majority of patients suffering from OC die of progressively chemo-resistance disease within 5 years from diagnosis. However, there is a minority of OC patients who are long-term (LT) survivors (>10 years). This includes ~15% of advanced stage tumors and ~75% of early-stage disease. The determinants for long term survival are thought to be both tumor and host based. Tumor characteristics contribute to the success of up-front therapy including
surgical outcome. Indeed, survival of patients with no residual disease (R0) was shown to correlate with the spread of the primary tumor, and a distinct genomic signature characteristic of tumor that cannot be optimally debulked was described. Host characteristics including environmental factors such as stress and exercise are likely to contribute too. There is little characterization of genomic/biologic tumor features or patient-reported outcomes that characterize LT survivors. Characterization of LT survivors, including: molecular and clinical
pathways, their longitudinal health-related QOL reports, and their short- and long-term response to treatments, will provide significant measures of prognostic factors that can be targeted to help women who have shorter survivals. Identification of women with high-grade, early stage OC who will recur allows tailoring therapy to only those who will benefit. Thus, the systematic molecular and patient-reported outcomes evaluation of LT survivors of OC (both early and advanced stage) will yield data for improved management of OC patients.

W81XWH-16-2-0038

2021-03-15

2022-12-25